NASDAQ:RARE
Ultragenyx Pharmaceutical Inc. Stock News
$40.90
-0.320 (-0.776%)
At Close: May 10, 2024
Ultragenyx (RARE) Presents Preliminary 2020 Revenues & Guidance
11:17am, Tuesday, 12'th Jan 2021
Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.
Durable and Clinically Meaningful Responses Reported from Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC
Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference
08:31am, Tuesday, 05'th Jan 2021
NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rar
Ultragenyx (RARE) Surges on Product Approvals, Pipeline Progress
10:41am, Monday, 04'th Jan 2021
Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.
5 Biotech Stocks That Have Gained More Than 200% in 2020
10:32am, Tuesday, 29'th Dec 2020
Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.
7 Penny Stocks on a Tear Right Now and Still Worth Buying
07:31am, Tuesday, 29'th Dec 2020
Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.
Ultragenyx: Upside But Not Without Risk
08:06pm, Monday, 21'st Dec 2020
The recent acquisition of rare dug heavyweight Alexion Pharmaceuticals signals a willingness of big pharma to enter the field. Typically, big pharma was interested in larger patient populations howeve
5 Biotech Stocks That More Than Doubled This Year
09:47am, Monday, 21'st Dec 2020
The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.
Ultragenyx (RARE), Mereo Ink Deal for Bone Disease Candidate
12:02pm, Friday, 18'th Dec 2020
Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.
Ultragenyx and Mereo BioPharma Announce Collaboration and License Agreement for Setrusumab in Osteogenesis Imperfecta
04:05pm, Thursday, 17'th Dec 2020
Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise
Ultragenyx Announces Orphan Drug Designation for UX701 for the Treatment of Wilson Disease
04:05pm, Wednesday, 09'th Dec 2020
NOVATO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare
GeneTx and Ultragenyx Announce Presentation of Phase 1/2 Data on Investigational GTX-102 in Patients with Angelman Syndrome
01:00pm, Saturday, 05'th Dec 2020
Results presented at Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit
State-of-the-art facility to be located in Bedford, Massachusetts
Ultragenyx to Present at Upcoming Investor Conferences
08:31am, Thursday, 05'th Nov 2020
NOVATO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri
NOVATO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serio
